Table 2.
Estimates of the effect of mastectomy relative to breast conserving surgery with radiation on 7-year survival by estimator and sample subsets1.
Estimator | ||||||
---|---|---|---|---|---|---|
Estimation Sample | N | Mastectomy percentage | Linear probability estimates2 | Instrumental variable estimates3 | ||
(1st–5th quintile range) | Mastectomy effect on 7-year survival (std. error) | Instrument chow test [44] F-value | Over identification test F-value |
Mastectomy effect on 7-year survival (std. error) | ||
Full sample | 28,675 | 56.2 | −0.030* | 264.01* | 0.60 | −0.071* |
(37.9–68.6) | (0.006) | (0.029) | ||||
Trial status comparable4 | ||||||
Yes | 5,003 | 43.5 | −0.001 | 50.43∗ | 0.57 | 0.05 |
(25.5–57.0) | (0.010) | (0.05) | ||||
No | 23,672 | 58.8 | −0.037* | 215.60∗ | 0.38 | −0.10* |
(40.4–71.1) | (0.006) | (0.03) | ||||
Stage | ||||||
Stage I | 17,908 | 47.3 | −0.017* | 174.75∗ | 0.93 | −0.02 |
(28.2–61.3) | (0.006) | (0.03) | ||||
Stage IIa | 7,700 | 67.2 | −0.049* | 63.02∗ | 1.28 | −0.15* |
(50.3–78.5) | (0.011) | (0.06) | ||||
Stage IIb | 2,827 | 80.2 | −0.085* | 23.81∗ | 2.03 | −0.22 |
(66.4–88.7) | (0.023) | (0.13) | ||||
Age | ||||||
66–70 | 8,037 | 50.9 | −0.010 | 75.53∗ | 1.99 | 0.02 |
(33.5–64.3) | (0.009) | (0.05) | ||||
71–75 | 8,405 | 51.4 | −0.016 | 81.82∗ | 0.15 | −0.05 |
(31.4–64.1) | (0.010) | (0.05) | ||||
76–80 | 6,611 | 57.5 | −0.049* | 69.94∗ | 0.42 | −0.11 |
(39.9–71.2) | (0.012) | (0.06) | ||||
81+ | 5,622 | 69.2 | −0.065* | 37.15∗ | 1.06 | −0.19* |
(52.3–78.6) | (0.015) | (0.09) |
1All models also specified all measured covariates listed in the variable definition section and are more fully described in Keating et al. [8].
2Average treatment effect on the treated (ATT). In this case, average effect of mastectomy on 7-year survival for those patients choosing mastectomy.
3Local average treatment effect (LATE). The average effect of mastectomy on 7-year survival for those patients whose mastectomy choice would have changed with local area mastectomy practice style.
4ESBC patients with low-risk tumors (stage I), little comorbid illness, and age ≤ 70.
*P < 0.05.